title: Trabectedin: A drug from the sea that strikes tumor-associated macrophages.
abstract: Tumor-associated macrophages (TAMs) and other myeloid cells that infiltrate neoplastic lesions promote tumor progression and are associated with poor patient prognosis. We have recently demonstrated that trabectedin, a licensed and commercially available anticancer agent, is selectively cytotoxic for TAMs and their circulating precursors (monocytes). The macrophage-depleting effect of trabectedin is a key component of its antitumor activity.
authors.affiliation: Clinical and Research Institute Humanitas; Rozzano, Milan, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Allavena
authors.forename: Giovanni
authors.initials: G
authors.lastname: Germano
authors.forename: Cristina
authors.initials: C
authors.lastname: Belgiovine
authors.forename: Maurizio
authors.initials: M
authors.lastname: D'Incalci
authors.forename: Alberto
authors.initials: A
authors.lastname: Mantovani
keywords: angiogenesis; chemotherapy; marine drug; micro-environment; tumor-associated macrophages
references.citation: Cancer Cell. 2013 Feb 11;23(2):249-62
references.pmid: 23410977
references.citation: Cancer Cell. 2013 Mar 18;23(3):277-86
references.pmid: 23518347
references.citation: Cancer Discov. 2011 Jun;1(1):54-67
references.pmid: 22039576
references.citation: Nature. 2008 Jul 24;454(7203):436-44
references.pmid: 18650914
references.citation: J Clin Invest. 2012 Mar;122(3):787-95
references.pmid: 22378047
references.citation: Lancet Oncol. 2007 Jul;8(7):595-602
references.pmid: 17586092
references.citation: Mol Cancer Ther. 2010 Aug;9(8):2157-63
references.pmid: 20647340
references.citation: N Engl J Med. 2010 Mar 11;362(10):875-85
references.pmid: 20220182
references.citation: Cell. 2010 Apr 2;141(1):39-51
references.pmid: 20371344
references.citation: Eur J Cancer. 2012 Nov;48(16):3036-44
references.pmid: 22749255